RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 1.44 Million USD | 24.16% |
| 2021 | 1.16 Million USD | 13.51% |
| 2020 | 1.02 Million USD | 39.61% |
| 2019 | 735.08 Thousand USD | 1242.52% |
| 2018 | 54.75 Thousand USD | -91.38% |
| 2017 | 634.85 Thousand USD | -21.82% |
| 2016 | 812.02 Thousand USD | 17.88% |
| 2015 | 688.85 Thousand USD | 21.7% |
| 2014 | 566.02 Thousand USD | 30.86% |
| 2013 | 432.54 Thousand USD | 56.95% |
| 2012 | 275.59 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 301.72 Thousand USD | -23.04% |
| 1998 | 392.04 Thousand USD | 256.41% |
| 1997 | 110 Thousand USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 1.49 Million USD | 3.33% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q2 | 1.25 Million USD | 3.85% |
| 2022 FY | 1.44 Million USD | 24.16% |
| 2022 Q4 | 1.44 Million USD | 4.15% |
| 2022 Q1 | 1.21 Million USD | 4.0% |
| 2022 Q3 | 1.38 Million USD | 10.37% |
| 2021 Q3 | 1.11 Million USD | -0.64% |
| 2021 Q4 | 1.16 Million USD | 4.34% |
| 2021 FY | 1.16 Million USD | 13.51% |
| 2021 Q2 | 1.12 Million USD | 4.54% |
| 2021 Q1 | 1.07 Million USD | 4.74% |
| 2020 Q2 | 920.34 Thousand USD | 21.2% |
| 2020 Q1 | 759.37 Thousand USD | 3.3% |
| 2020 FY | 1.02 Million USD | 39.61% |
| 2020 Q4 | 1.02 Million USD | 8.29% |
| 2020 Q3 | 947.69 Thousand USD | 2.97% |
| 2019 FY | 735.08 Thousand USD | 1242.52% |
| 2019 Q1 | 364.44 Thousand USD | 565.61% |
| 2019 Q2 | 683.69 Thousand USD | 87.6% |
| 2019 Q3 | 709.63 Thousand USD | 3.79% |
| 2019 Q4 | 735.08 Thousand USD | 3.59% |
| 2018 Q1 | 439.34 Thousand USD | -30.8% |
| 2018 FY | 54.75 Thousand USD | -91.38% |
| 2018 Q2 | 459.17 Thousand USD | 4.51% |
| 2018 Q3 | 51.43 Thousand USD | -88.8% |
| 2018 Q4 | 54.75 Thousand USD | 6.44% |
| 2017 FY | 634.85 Thousand USD | -21.82% |
| 2017 Q4 | 634.85 Thousand USD | -29.76% |
| 2017 Q3 | 903.89 Thousand USD | 3.55% |
| 2017 Q1 | 842.31 Thousand USD | 3.73% |
| 2017 Q2 | 872.93 Thousand USD | 3.64% |
| 2016 Q2 | 750.1 Thousand USD | 4.26% |
| 2016 Q1 | 719.47 Thousand USD | 4.45% |
| 2016 Q4 | 812.02 Thousand USD | 3.96% |
| 2016 FY | 812.02 Thousand USD | 17.88% |
| 2016 Q3 | 781.06 Thousand USD | 4.13% |
| 2015 FY | 688.85 Thousand USD | 21.7% |
| 2015 Q2 | 626.93 Thousand USD | 5.14% |
| 2015 Q1 | 596.3 Thousand USD | 5.35% |
| 2015 Q4 | 688.85 Thousand USD | 4.71% |
| 2015 Q3 | 657.89 Thousand USD | 4.94% |
| 2014 Q3 | 534.34 Thousand USD | 6.88% |
| 2014 FY | 566.02 Thousand USD | 30.86% |
| 2014 Q4 | 566.02 Thousand USD | 5.93% |
| 2014 Q2 | 499.96 Thousand USD | 7.3% |
| 2014 Q1 | 465.96 Thousand USD | 7.73% |
| 2013 Q3 | 400.94 Thousand USD | 36.59% |
| 2013 Q1 | 278.93 Thousand USD | 1.21% |
| 2013 FY | 432.54 Thousand USD | 56.95% |
| 2013 Q2 | 293.53 Thousand USD | 5.23% |
| 2013 Q4 | 432.54 Thousand USD | 7.88% |
| 2012 Q4 | 275.59 Thousand USD | 0.0% |
| 2012 FY | 275.59 Thousand USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 FY | - USD | -100.0% |
| 2000 Q1 | - USD | -100.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 FY | 301.72 Thousand USD | -23.04% |
| 1999 Q4 | 301.72 Thousand USD | 0.0% |
| 1998 Q1 | 220 Thousand USD | 100.0% |
| 1998 FY | 392.04 Thousand USD | 256.41% |
| 1998 Q4 | 390 Thousand USD | 0.0% |
| 1998 Q2 | 280 Thousand USD | 27.27% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q3 | 50 Thousand USD | 0.0% |
| 1997 Q4 | 110 Thousand USD | 120.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 FY | 110 Thousand USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 96.49% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 64.912% |
| SQZ Biotechnologies Company | 27.47 Million USD | 94.735% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 96.665% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 95.141% |
| Mesoblast Limited | 118.7 Million USD | 98.782% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -52.522% |
| Genus plc | 233.1 Million USD | 99.38% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 50.644% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -7.646% |
| Marizyme, Inc. | 18.71 Million USD | 92.273% |
| ContraFect Corporation | 2.88 Million USD | 49.798% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -92.843% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -967.497% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 37.818% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 74.439% |
| MultiCell Technologies, Inc. | 202.58 USD | -713849.551% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 97.484% |
| EV Biologics, Inc. | 1.49 Million USD | 3.24% |
| Q BioMed Inc. | 4.1 Million USD | 64.81% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 95.631% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -129.546% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -17.744% |
| Biomind Labs Inc. | 735.54 Thousand USD | -96.633% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.157% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 88.872% |
| Skye Bioscience, Inc. | 4.61 Million USD | 68.662% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -62.862% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -922.004% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 75.365% |
| IMV Inc. | 28.88 Million USD | 94.993% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -5523.543% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 35.958% |
| GB Sciences, Inc. | 1.75 Million USD | 17.79% |
| Alpha Cognition Inc. | 1.22 Million USD | -18.515% |
| HST Global, Inc. | 98.31 Thousand USD | -1371.047% |
| CSL Limited | 12.18 Billion USD | 99.988% |
| Halberd Corporation | 150 Thousand USD | -864.213% |
| Enzolytics Inc. | 996.33 Thousand USD | -45.163% |
| Resverlogix Corp. | 6.49 Million USD | 77.718% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -202.894% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -465.87% |
| argenx SE | 20 Million USD | 92.768% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 96.825% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 46.605% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -14044.929% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.654% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -620.939% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 39.68% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -530.779% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 97.862% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 52.207% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -302.079% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 92.885% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -872.943% |
| BioStem Technologies, Inc. | 4.71 Million USD | 69.302% |
| ONE Bio Corp. | 19.71 Million USD | 92.664% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -478.107% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -481.505% |
| Agentix Corp. | 50 Thousand USD | -2792.638% |
| LadRx Corporation | 33.6 Thousand USD | -4203.752% |
| Cell Source, Inc. | 9.25 Million USD | 84.371% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -91.26% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -91.26% |
| NovAccess Global Inc. | 2.19 Million USD | 34.255% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 79.551% |
| Itoco Inc. | 228.37 Thousand USD | -533.303% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -585.54% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 70.975% |
| Kadimastem Ltd | 891.22 Thousand USD | -62.284% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -259.916% |
| CytoDyn Inc. | 30.07 Million USD | 95.191% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -198.651% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -311.065% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 81.505% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1080.669% |
| Rebus Holdings, Inc. | 310 Thousand USD | -366.555% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 69.457% |
| International Stem Cell Corporation | 4.17 Million USD | 65.383% |
| Bioxytran, Inc. | 1.92 Million USD | 24.867% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2217.336% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 33.682% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 82.608% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 83.153% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 7.018% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -439.671% |
| Neutra Corp. | 54.15 Thousand USD | -2570.653% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 20.966% |
| PureTech Health plc | 25.51 Million USD | 94.331% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -18.142% |
| IXICO plc | 472.02 Thousand USD | -206.409% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 90.67% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 97.677% |
| CSL Limited | 12.18 Billion USD | 99.988% |
| Cellectis S.A. | 92.77 Million USD | 98.441% |